New eye drop shows promise for dry eye sufferers

NCT ID NCT03066219

Completed Symptom relief Sponsor: BRIM Biotechnology Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether BRM421 eye drops can safely ease the signs and symptoms of dry eye. 157 adults with dry eye for at least 6 months received either the active drops or a placebo. The trial measured changes in corneal staining and discomfort scores. Results suggest the drops may help reduce eye surface damage and discomfort.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BRM421 ophthalmic solution
What this could lead to: If successful, this could lead to a new eye drop treatment that reduces dry eye symptoms and corneal damage.
What could go wrong: This is an early Phase 2 trial with only 157 participants. The results may not hold up in larger studies, and the effect over placebo was modest.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DRY EYE SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dry eye syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DRY EYE SYNDROME

Contacts and locations

Locations

Andover Eye Associates

Andover, Massachusetts, 01810, United States
Central Maine Eye Care

Lewiston, Maine, 04240, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.